System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Clinical Trial, Phase III Journal Article Randomized Controlled Trial Epublish

PubMed: 42292352 DOI: 10.3389/fimmu.2026.1771848

Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis.

Front Immunol 17:1771848

Authors: Derrick Robertson, Enrique Alvarez, Lawrence Steinman, Hans-Peter Hartung, Peiqing Qian, Krzysztof Selmaj, Sibyl Wray, Daniel Wynn, Edward J Fox, Koby Mok, Hari P Miskin, Yihuan Xu, Christopher A Garner, Bruce A C Cree

Affiliations

  • University of South Florida, Tampa, FL, United States.
  • University of Colorado, Aurora, CO, United States.
  • Stanford University, Stanford, CA, United States.
  • Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Brain and Mind Centre, University of Sydney, Sydney, Australia.
  • Medical University of Vienna, Vienna, Austria.
  • Palacký University Olomouc, Olomouc, Czechia.
  • Swedish Medical Center, Seattle, WA, United States.
  • Center of Neurology, Lodz, Poland.
  • University of Warmia and Mazury, Olsztyn, Poland.
  • Hope Neurology, Knoxville, TN, United States.
  • Consultants in Neurology, Northbrook, IL, United States.
  • TG Therapeutics, Morrisville, NC, United States.
  • UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, United States.

Abstract

BACKGROUND

Evidence suggests that treating relapsing multiple sclerosis (RMS) initially with a high-efficacy disease-modifying therapy (DMT) is superior to an escalating approach at reducing disability progression and relapse rate.

OBJECTIVES

To evaluate the efficacy of ublituximab versus teriflunomide in participants without prior DMT (treatment-naïve population) and in a subset of treatment-naïve participants with symptom onset ≤ three years (early treatment subpopulation).

METHODS

Pooled post hoc analyses of ULTIMATE I/II were conducted at Week 96.

RESULTS

The annualized relapse rate was 0.081 for ublituximab (n = 345) versus 0.188 for teriflunomide (n = 377) (p < 0.001) in the treatment-naïve population and 0.130 for ublituximab (n = 139) versus 0.334 for teriflunomide (n = 140) in the early treatment subpopulation (p = 0.004). Twelve-week confirmed disability improvement rates were 10.7% versus 5.3% (p = 0.010) in the treatment-naïve population and 14.4% versus 3.6% (p = 0.002) in the early treatment population (ublituximab vs. teriflunomide). Significant reductions in gadolinium-enhancing T1 lesions and new/enlarging T2 lesions, respectively, occurred for ublituximab versus teriflunomide (treatment naïve: 0.031 vs. 0.791 and 0.390 vs. 4.144; p < 0.001 for both; early treatment: 0.051 vs. 1.030 and 0.508 vs. 6.068; p < 0.001 for both).

CONCLUSIONS

Ublituximab was associated with significant treatment benefits at Week 96 in treatment-naïve participants and those receiving treatment within three years of symptom onset.

CLINICAL TRIAL REGISTRATION

https://clinicaltrials.gov/study/NCT03277261 and https://clinicaltrials.gov/study/NCT03277248, identifiers NCT03277261 and NCT03277248.

MeSH

Sclerosis, Multiple Sclerosis, Antibodies, Monoclonal, Therapeutics, Wounds And Injuries